The ocular endothelin system: A novel target for the treatment of endotoxin-induced uveitis with bosentan

Investigative Ophthalmology and Visual Science

Volumn 55, Issue 6, 2014, Pages 3517-3524

  Keles, Sadullah ^a   Halici, Zekai ^a   Atmaca, Hasan Tarik ^b   Yayla, Muhammed ^a   Yildirim, Kenan ^c   Ekinci, Metin ^d   Akpinar, Erol ^a   Altuner, Durdu ^e   Cakici, Ozgur ^f   Bayraktutan, Zafer ^g  

^a ATATÜRK UNIVERSITY   (Turkey)

^b KIRIKKALE UNIVERSITY   (Turkey)

^c Igdir State Hospital   (Turkey)

^d KAFKAS UNIVERSITY   (Turkey)

^e RECEP TAYYIP ERDOGAN UNIVERSITY   (Turkey)

^f MUGLA SITKI KOCMAN UNIVERSITY   (Turkey)

^g Department of Ophthalmology Mugla Sitki Kocaman University ^*  (Turkey)

Author keywords

Bosentan; Endothelin 1; Endotoxin induced uveitis; TNF iNOS

Indexed keywords

BOSENTAN; COMPLEMENTARY DNA; CYTOKINE; DEXAMETHASONE; ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR A; LIPOPOLYSACCHARIDE; NITRIC OXIDE SYNTHASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; AQUEOUS HUMOR; ARTICLE; CONTROLLED STUDY; ENDOTOXIN-INDUCED UVEITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EYE INFLAMMATION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION;

BOSENTAN; ENDOTHELIN-1; ENDOTOXIN-INDUCED UVEITIS; INOS; TNF-Α;

ANIMALS; AQUEOUS HUMOR; DEXAMETHASONE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ENDOTHELINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GLUCOCORTICOIDS; MALE; RATS; RATS, WISTAR; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, ENDOTHELIN; RNA; SULFONAMIDES; TREATMENT OUTCOME; UVEITIS;

EID: 84902245892     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.14-14193     Document Type: Article

References (59)

1. Forrester JV. Autoimmunity and autoimmune disease of the eye. Dev Ophthalmol. 1999;30:167-186.
2. Rosenbaum JT. Uveitis. An internist's view. Arch Intern Med. 1989;149:1173-1176.
3. De Smet MD, Chan CC. Regulation of ocular inflammation-what experimental and human studies have taught us. Prog Retin Eye Res. 2001;20:761-797.
4. Lightman S. Uveitis: what do we know and how does it help? Clin Experiment Ophthalmol. 2001;29:48-51.
5. Boyd SR, Young S, Lightman S. Immunopathology of the noninfectious posterior and intermediate uveitides. Surv Ophthalmol. 2001;46:209-233.
6. Yang S, Lu H, Wang J, Qi X, Liu X, Zhang X. The effect of tolllike receptor 4 on macrophage cytokines during endotoxin induced uveitis. Int J Mol Sci. 2012;13:7508-7520.
7. Toguri JT, Lehmann C, Laprairie RB, et al. Anti-inflammatory effects of cannabinoid 2 receptor activation in endotoxininduced uveitis. Br J Pharmacol. 2013;171:1448-1461.
8. Okunuki Y, Usui Y, Nagai N, et al. Suppression of experimental autoimmune uveitis by angiotensin II type 1 receptor blocker telmisartan. Invest Ophthalmol Vis Sci. 2009;50:2255-2261.
9. Thorin E, Clozel M. The cardiovascular physiology and pharmacology of endothelin-1. Adv Pharmacol. 2010;60:1-26.
10. Chakravarthy U, Douglas AJ, Bailie JR, McKibben B, Archer DB. Immunoreactive endothelin distribution in ocular tissues. Invest Ophthalmol Vis Sci. 1994;35:2448-2454.
11. Ripodas A, de Juan JA, Roldan-Pallares M, et al. Localisation of endothelin-1 mRNA expression and immunoreactivity in the retina and optic nerve from human and porcine eye. Evidence for endothelin-1 expression in astrocytes. Brain Res. 2001; 912:137-143.
12. Stitt AW, Chakravarthy U, Gardiner TA, Archer DB. Endothelinlike immunoreactivity and receptor binding in the choroid and retina. Curr Eye Res. 1996;15:111-117.
13. Narayan S, Brun AM, Yorio T. Endothelin-1 distribution and basolateral secretion in the retinal pigment epithelium. Exp Eye Res. 2004;79:11-19.
14. Narayan S, Prasanna G, Krishnamoorthy RR, Zhang X, Yorio T. Endothelin-1 synthesis and secretion in human retinal pigment epithelial cells (ARPE-19): differential regulation by cholinergics and TNF-alpha. Invest Ophthalmol Vis Sci. 2003;44:4885-4894.
15. Okafor MC, Mukhopadhyay P, Delamere NA. Studies on endothelin release and Na, K transport in porcine lens. Invest Ophthalmol Vis Sci. 2002;43:790-796.
16. Zhang X, Clark AF, Yorio T. Interactions of endothelin-1 with dexamethasone in primary cultured human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2003;44:5301-5308.
17. Wollensak G, Schaefer HE, Ihling C. An immunohistochemical study of endothelin-1 in the human eye. Curr Eye Res. 1998; 17:541-545.
18. Fernandez-Durango R, Rollin R, Mediero A, et al. Localization of endothelin-1 mRNA expression and immunoreactivity in the anterior segment of human eye: expression of ETA and ETB receptors. Mol Vis. 2003;9:103-109.
19. Sasaoka M, Taniguchi T, Shimazawa M, Ishida N, Shimazaki A, Hara H. Intravitreal injection of endothelin-1 caused optic nerve damage following to ocular hypoperfusion in rabbits. Exp Eye Res. 2006;83:629-637.
20. Cioffi GA, Orgul S, Onda E, Bacon DR, Van Buskirk EM. An in vivo model of chronic optic nerve ischemia: the dosedependent effects of endothelin-1 on the optic nerve microvasculature. Curr Eye Res. 1995;14:1147-1153.
21. Polak K, Petternel V, Luksch A, et al. Effect of endothelin and BQ123 on ocular blood flow parameters in healthy subjects. Invest Ophthalmol Vis Sci. 2001;42:2949-2956.
22. Lepple-Wienhues A, Becker M, Stahl F, et al. Endothelin-like immunoreactivity in the aqueous humour and in conditioned medium from cultured ciliary epithelial cells. Curr Eye Res. 1992;11:1041-1046.
23. Imhof AK, Gluck L, Gajda M, Brauer R, Schaible HG, Schulz S. Potent anti-inflammatory and antinociceptive activity of the endothelin receptor antagonist bosentan in monoarthritic mice. Arthritis Res Ther. 2011;13:R97.
24. Comellas AP, Briva A. Role of endothelin-1 in acute lung injury. Transl Res. 2009;153:263-271.
25. Shoji N, Oshika T, Masuda K. Endothelin-1 and intraocular inflammation in pigmented rabbit eyes. Jpn J Ophthalmol. 1997;41:150-153.
26. Yadav UC, Subramanyam S, Ramana KV. Prevention of endotoxin-induced uveitis in rats by benfotiamine, a lipophilic analogue of vitamin B1. Invest Ophthalmol Vis Sci. 2009;50: 2276-2282.
27. Sengul O, Ferah I, Polat B, et al. Blockade of endothelin receptors with bosentan limits ischaemia/reperfusion-induced injury in rat ovaries. Eur J Obstet Gynecol Reprod Biol. 2013; 170:458-463.
28. Araz O, Demirci E, Yilmazel Ucar E, et al. Comparison of reducing effect on lung injury of dexamethasone and bosentan in acute lung injury: an experimental study. Multidiscip Respir Med. 2013;8:74.
29. Tilton RG, Chang K, Corbett JA, et al. Endotoxin-induced uveitis in the rat is attenuated by inhibition of nitric oxide production. Invest Ophthalmol Vis Sci. 1994;35:3278-3288.
30. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T) Method. Methods. 2001;25:402-408.
31. Bierly JR, Nozik RA. Management of uveitis. Curr Opin Ophthalmol. 1992;3:527-533.
32. De Vos AF, van Haren MA, Verhagen C, Hoekzema R, Kijlstra A. Kinetics of intraocular tumor necrosis factor and interleukin-6 in endotoxin-induced uveitis in the rat. Invest Ophthalmol Vis Sci. 1994;35:1100-1106.
33. De Vos AF, Hoekzema R, Kijlstra A. Cytokines and uveitis, a review. Curr Eye Res. 1992;11:581-597.
34. Franks WA, Limb GA, Stanford MR, et al. Cytokines in human intraocular inflammation. Curr Eye Res. 1992;11(suppl):187-191.
35. Bellot JL, Palmero M, Garcia-Cabanes C, Espi R, Hariton C, Orts A. Additive effect of nitric oxide and prostaglandin-E2 synthesis inhibitors in endotoxin-induced uveitis in the rabbit. Inflamm Res. 1996;45:203-208.
36. Gholamnezhad Z, Koushyar H, Byrami G, Boskabady MH. The extract of crocus sativus and its constituent safranal, affect serum levels of endothelin and total protein in sensitized guinea pigs. Iran J Basic Med Sci. 2013;16:1022-1026.
37. Lehrke I, Waldherr R, Ritz E, Wagner J. Renal endothelin-1 and endothelin receptor type B expression in glomerular diseases with proteinuria. J Am Soc Nephrol. 2001;12:2321-2329.
38. Herman WH, Emancipator SN, Rhoten RL, Simonson MS. Vascular and glomerular expression of endothelin-1 in normal human kidney. Am J Physiol. 1998;275:8-17.
39. Ergul A. Endothelin-1 and diabetic complications: focus on the vasculature. Pharmacol Res. 2011;63:477-482.
40. Saleh MA, Boesen EI, Pollock JS, Savin VJ, Pollock DM. Endothelin receptor A-specific stimulation of glomerular inflammation and injury in a streptozotocin-induced rat model of diabetes. Diabetologia. 2011;54:979-988.
41. Juergens UR, Racke K, Uen S, et al. Inflammatory responses after endothelin B (ETB) receptor activation in human monocytes: new evidence for beneficial anti-inflammatory potency of ETB-receptor antagonism. Pulm Pharmacol Ther. 2008;21:533-539.
42. Sasser JM, Sullivan JC, Hobbs JL, et al. Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism. J Am Soc Nephrol. 2007;18:143-154.
43. Abbas AK, Lichtman AH, Pober, JS. Cellular and Molecular Immunology. 3rd ed. Philadelphia, PA: W.B. Saunders Company; 1997.
44. Sun M, Yang Y, Yang P, Lei B, Du L, Kijlstra A. Regulatory effects of IFN-beta on the development of experimental autoimmune uveoretinitis in B10RIII mice. PLoS One. 2011; 6:e19870.
45. Ruetten H, Thiemermann C. Endothelin-1 stimulates the biosynthesis of tumour necrosis factor in macrophages: ETreceptors, signal transduction and inhibition by dexamethasone. J Physiol Pharmacol. 1997;48:675-688.
46. Yang TL, Chen MF, Jiang JL, Xie QY, Li YP, Li YJ. The endothelin receptor antagonist decreases ischemia/reperfusion-induced tumor necrosis factor production in isolated rat hearts. Int J Cardiol. 2005;100:495-498.
47. Song M, Kellum JA, Kaldas H, Fink MP. Evidence that glutathione depletion is a mechanism responsible for the anti-inflammatory effects of ethyl pyruvate in cultured lipopolysaccharide-stimulated RAW 264.7 cells. J Pharmacol Exp Ther. 2004;308:307-316.
48. Donate PB, Cunha TM, Verri WA, et al. Bosentan, an endothelin receptor antagonist, ameliorates collagen-induced arthritis: the role of TNF-alpha in the induction of endothelin system genes. Inflamm Res. 2012;61:337-348.
49. Yayla M, Halici Z, Unal B, Bayir Y, Akpinar E, Gocer F. Protective effect of Et-1 receptor antagonist bosentan on paracetamol induced acute liver toxicity in rats. Eur J Pharmacol. 2014;726C:87-95.
50. Prado CM, Leick-Maldonado EA, Arata V, Kasahara DI, Martins MA, Tiberio IF. Neurokinins and inflammatory cell iNOS expression in guinea pigs with chronic allergic airway inflammation. Am J Physiol Lung Cell Mol Physiol. 2005; 288:741-748.
51. Huang L, Si XM, Feng JX. NF-kappaB related abnormal hyperexpression of iNOS and NO correlates with the inflammation procedure in biliary atresia livers. Pediatr Surg Int. 2010;26: 899-905.
52. Downey D, Elborn JS. Nitric oxide, iNOS, and inflammation in cystic fibrosis. J Pathol. 2000;190:115-116.
53. Bachmaier K, Neu N, Pummerer C, et al. iNOS expression and nitrotyrosine formation in the myocardium in response to inflammation is controlled by the interferon regulatory transcription factor 1. Circulation. 1997;96:585-591.
54. Duygulu F, Evereklioglu C, Calis M, Borlu M, Cekmen M, Ascioglu O. Synovial nitric oxide concentrations are increased and correlated with serum levels in patients with active Behcet's disease: a pilot study. Clin Rheumatol. 2005;24:324-330.
55. Mandai M, Yoshimura N, Yoshida M, Iwaki M, Honda Y. The role of nitric oxide synthase in endotoxin-induced uveitis: effects of NG-nitro L-arginine. Invest Ophthalmol Vis Sci. 1994;35:3673-3680.
56. Teplyakov AI. Endothelin-1 involved in systemic cytokine network inflammatory response at atherosclerosis. J Cardiovasc Pharmacol. 2004;44:274-275.
57. Skalska AB, Pietrzycka A, Stepniewski M. Correlation of endothelin 1 plasma levels with plasma antioxidant capacity in elderly patients treated for hypertension. Clin Biochem. 2009;42:358-364.
58. Voerman HJ, Stehouwer CD, van Kamp GJ, Strack van Schijndel RJ, Groeneveld AB, Thijs LG. Plasma endothelin levels are increased during septic shock. Crit Care Med. 1992; 20:1097-1101.
59. Keller S, Karaa A, Paxian M, Clemens MG, Zhang JX. Inhibition of endothelin-1-mediated up-regulation of iNOS by bosentan ameliorates endotoxin-induced liver injury in cirrhosis. Shock. 2006;25:306-313.